DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced that the results from the first stage of a multicenter Phase 2 clinical study of Lymphoseek® support the commencement of enrollment in the second stage of the Phase 2 study. Lymphoseek is a proprietary radioactive tracing agent being developed for use in connection with gamma detection devices in a surgical procedure known as Intraoperative Lymphatic Mapping (ILM). This study, which is evaluating the efficacy and safety of Lymphoseek in patients with either melanoma or breast cancer, is being conducted in two stages. In accordance with the protocol, having obtained positive results in the first stage of the trial (Lymphoseek identified lymphatic tissue in over 97% of treated patients), Neoprobe has commenced the second stage of the study. This stage will involve an additional 40 patients with either melanoma or breast cancer; patients are now being enrolled at all five of the cancer centers in the United States participating in the study. Neoprobe is also preparing to submit its Phase 3 protocol and related materials to FDA.
